Skip to main content
MRK
NYSE Life Sciences

默克的Welireg-Keytruda组合获得FDA优先审查，6月PDUFA截止日期

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$123.31
Mkt Cap
$306.132B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

FDA已经为默克的Welireg和Keytruda联合治疗设定了2026年6月19日的PDUFA截止日期，并授予其优先审查资格，用于治疗早期肾细胞癌。 这一决定是在临床试验结果显示，该联合治疗方案相比Keytruda单一治疗减少了疾病复发或死亡的风险28%之后做出的。 这一进展增加了默克最近的积极肿瘤学新闻，包括其他有前途的Keytruda联合治疗方案和Welireg-Lenvima治疗方案。 潜在的批准将显著扩大Keytruda和Welireg的市场，进一步巩固默克在肿瘤学领域的领先地位。 交易者将密切关注FDA在PDUFA截止日期前的决定。

在该公告发布时，MRK的交易价格为$123.31，交易所为NYSE，所属行业为Life Sciences，市值约为$3061.3亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article